The isotretinoin drugs market has seen considerable growth due to a variety of factors.
• The isotretinoin drugs market has experienced significant growth in recent years. It will increase from $1.29 billion in 2024 to $1.36 billion in 2025, growing at a CAGR of 5.8%.
This growth can be attributed to the prevalence of severe acne, the effectiveness of isotretinoin, increased awareness and marketing campaigns, regulatory approvals, and more visits to dermatologists.
The isotretinoin drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The isotretinoin drugs market is set for robust growth, reaching $1.69 billion by 2029, with a CAGR of 5.5%.
Growth is driven by increased awareness of skincare trends, the rise in acne incidence, the aging population, and a focus on mental well-being. Key trends include ongoing R&D, technological advancements, innovations in generic drugs, improved formulations, and dermatology advancements.
The isotretinoin drugs market is likely to grow due to rising cases of skin cancer, which results from uncontrolled skin cell growth, often caused by prolonged UV exposure. Factors like ozone layer depletion and lifestyle changes are contributing to this rise. Isotretinoin drugs help prevent and treat skin cancer by reducing the abnormal proliferation of skin cells. For example, the American Cancer Society reported in January 2024 that skin cancer cases in the U.S. will rise to 108,270, marking a 3.2% increase from 2023. Thus, the increasing skin cancer cases are boosting the isotretinoin drugs market.
The isotretinoin drugs market covered in this report is segmented –
1) By Form: Capsules, Injection
2) By Indication Type: Severe Acne, Neuroblastoma, Cutaneous T-Cell Lymphoma, Harlequin Ichthyosis, Xeroderma Pigmentosum, Fibrodysplasia Ossificans Progressiva, Squamous Cell Skin Cancers, Other Indication Types
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Capsules: Soft Gel Capsules, Hard Gel Capsules, Liquid-Filled Capsules
2) By Injection: Intravenous Injection, Intramuscular Injection
Key players in the isotretinoin drugs market are concentrating on the development of superior formulations like isotretinoin capsules in a bid to improve treatment alternatives and make them more accessible to patients. These capsules are typically prescribed for extreme acne conditions such as nodular or cystic acne, although their usage is strictly regulated due to their potential significant side effects, particularly a high risk of birth defects. For example, in July 2023, Upsher-Smith Laboratories, LLC, an American pharmaceutical company, introduced their first Isotretinoin Capsules USP, available in dosages of 10 mg, 20 mg, 30 mg, and 40 mg. These capsules are therapeutically equivalent (TE code AB1) to the brand Accutane, providing an effective treatment option for severe acne.
Major companies operating in the isotretinoin drugs market are:
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Hetero Drugs Ltd.
• Sun Pharmaceuticals Industries Limited
• Intas Pharmaceuticals Ltd.
• Aurobindo Pharma
• Dr. Reddy’s Laboratories Ltd.
• Cipla Limited
• Amneal Pharmaceuticals LLC
• Lupin Pharmaceuticals Inc
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals
• Alkem Laboratories
• Torrent Pharmaceuticals Ltd
• Almirall LLC
• Alembic Pharmaceuticals Ltd
• Ajanta Pharma Ltd
• Strides Pharma Science Limited
• Wockhardt Ltd.
• Douglas Pharmaceuticals Limited
• Chongqing Huapont Pharm Co. Ltd.
• Cipher Pharmaceuticals Inc.
• Vidhyasha Pharmaceuticals
North America was the largest region in the isotretinoin drugs market in 2024. The regions covered in the isotretinoin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.